Real‐World Experience of Dupilumab in Children and Adolescents With Atopic Dermatitis in Argentina

Current treatment guidelines suggest that patients with moderate-to-severe atopic dermatitis (AD) should be treated with systemic therapies, but evidence on its effectiveness in Latin America is limited. A nationwide, web-based survey was distributed among dermatologists managing children and adolescents with moderate-to-severe AD treated with dupilumab in Argentina to characterize and describe children and adolescents with AD who received dupilumab in a real-world setting. Data from 41 patients (median age: 11.23 years; female: 56.1%) revealed that 61% had developed AD by the age of 1 year or younger; atopic comorbidities were present in 70.7% (asthma 48.8%); methotrexate was the most frequently prescribed systemic therapy (58.5%); the median age at dupilumab initiation was 10 years (interquartile range [IQR]: 6.5-15) and median treatment duration was 1 year (IQR: 0-2). We conclude that treatment with dupilumab was highly effective in controlling moderate-to-severe AD refractory to conventional, guideline-recommended systemic therapies, with adequate control in 87.8% of cases.